Hemic and Lymphatic Diseases: Clinical Trials

29,601 trials for Hemic and Lymphatic Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13941 completed, 4006 recruiting, 3895 unknown, 3133 terminated. 10432 Phase 2, 7230 Phase 1, 4002 Not applicable, 3287 Phase 3, 1116 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 210432Completed 4684, Terminated 1488, Recruiting 1382, Unknown 1134, Active not recruiting 798, Withdrawn 480, Not yet recruiting 398, Suspended 39, Enrolling by invitation 29
Phase 17230Completed 3255, Terminated 1154, Recruiting 997, Unknown 674, Active not recruiting 507, Withdrawn 357, Not yet recruiting 219, Suspended 51, Enrolling by invitation 16
Not applicable4002Completed 1903, Unknown 635, Recruiting 593, Not yet recruiting 264, Terminated 252, Active not recruiting 173, Withdrawn 133, Enrolling by invitation 36, Suspended 13
Phase 33287Completed 1725, Unknown 402, Recruiting 359, Terminated 337, Active not recruiting 248, Not yet recruiting 111, Withdrawn 87, Enrolling by invitation 10, Suspended 8
Phase 41116Completed 562, Unknown 235, Recruiting 99, Terminated 97, Withdrawn 47, Not yet recruiting 46, Active not recruiting 25, Enrolling by invitation 4, Suspended 1
Early Phase 1466Recruiting 106, Completed 102, Unknown 101, Not yet recruiting 59, Terminated 46, Active not recruiting 24, Withdrawn 20, Suspended 6, Enrolling by invitation 2

Follow Hemic and Lymphatic Diseases: new trials by email Literature Review of Hemic and Lymphatic Diseases trials Research Report on Hemic and Lymphatic Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
FLASH Pilot Phase 1 Safety Study
IntraOp Mobetron UHDR, Linac - Cutaneous Lymphoma
Not applicableNot yet recruitingLesley A. Jarvis102029-10-312026-11-16
Sonrotoclax in Combination With Azacitidine for Previously Untreated Higher-risk Myelodysplastic Syndromes
Each treatment cycle is 28-days. Azacitidine 75 mg/m² is administered subcutaneously or intravenously on Days 1-7 of each cycle. Sonrotoclax is orally administered once daily on Days 1-14 within each - MDS (Myelodysplastic Syndrome)
Phase 2 / Phase 3Not yet recruitingThe Affiliated People's Hospital of Ningbo University102028-09-012026-11-12
A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia
Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia
Phase 3Not yet recruitingAmgen5602028-06-302026-09-15
Safety and Efficacy of KL003 Cell Injection in Severe Sickle Cell Disease
KL003 Cell Injection - Sickle Cell Disease
Not applicableSuspendedInstitute of Hematology & Blood Diseases Hospital, China32028-03-012026-11-05
Pyronaridine in Acute Myeloid Leukemia (AML)
Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Phase 2SuspendedArmaceutica, Inc.2002028-02-212026-10-19
Effect of Ginger on Heavy Menstrual Bleeding in Women With Coagulation Disorders
Ginger, Placebo - Women With Coagulation Disorders
Early Phase 1Not yet recruitingUniversity of Valladolid742028-02-012026-05-19
MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma
Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway - Multiple Myeloma, Heart Disease Risk Factors
Not applicableNot yet recruitingUniversity of Vermont Medical Center332028-02-012026-08-25
Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML
Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion, Gemtuzumab Ozogamicin - Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 1Not yet recruitingGerman Cancer Research Center122028-01-012025-03-14
OPTIMAL LEAP: Optimizing Dihydroartemisinin-Piperaquine IPTsc Intervals to Advance Learning, Executive Function, Attendance, and Antimalarial Resistance Surveillance in Kenyan Schoolchildren
Monthly DP, Quarterly DP - Malaria, Asymptomatic Malaria
Phase 3Not yet recruitingIndiana University15002028-01-012026-09-01
Methadone as an Alternative Treatment for Children Underdoing HSCT
PCA plus methadone (Experimental), PCA Alone (SOC) - Leukemia, Aplastic Anemia
Phase 3SuspendedUniversity of Texas Southwestern Medical Center602028-01-012025-10-23
Prenatal Transplantation for Fetuses With Fanconi Anemia
IUHSCT for FA-affected fetuses - Fanconi Anemia, Anemia, Hypoplastic, Congenital
Phase 1 / Phase 2Not yet recruitingAgnieszka Czechowicz122028-01-012026-06-16
A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
Cytarabine, Oral Cladribine - Acute Myeloid Leukemia (AML)
Phase 1 / Phase 2Not yet recruitingM.D. Anderson Cancer Center582027-12-012026-08-25
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
YKST02 - Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 2Not yet recruitingExcyte Biopharma Ltd642027-12-012026-11-06
Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy
NM8074 - aHUS - Atypical Hemolytic Uremic Syndrome
Phase 2Not yet recruitingNovelMed Therapeutics122027-11-012026-04-13
Self-administered Acupressure in Patients With Sickle Cell Disease
Verum Acupressure (using AcuWand), Sham Acupressure (using AcuWand) - Sickle Cell Disease (SCD)
Not applicableNot yet recruitingUniversity of Cincinnati3002027-10-012026-10-15
The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma
Individual Exercise, Group Exercise - Multiple Myeloma
Not applicableSuspendedMedical University of Vienna452027-09-012026-10-09
Development of a Provider-Focused Intervention to Improve Health Outcomes in Pediatric Sickle Cell Disease
Individuation and Perspective-Taking (IPT), pediatric SCD pain management education session - Sickle Cell Disease, Sickle Cell Anemia in Children
Not applicableNot yet recruitingConnecticut Children's Medical Center302027-09-012026-04-29
Family-Focused Study to Support Medication for Opioid Use Disorder
FamilyCHESS, Standard of Care - Opioid Use Disorder, Opioid Use Disorder, Moderate
Not applicableNot yet recruitingUniversity of Wisconsin, Madison3382027-08-312026-07-07
Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2Not yet recruitingCity of Hope Medical Center442027-08-042026-09-10
Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy
• Sivelestat intravenous infusion, NaCl intravenous infusion - Septic Shock, Coagulopathy
Phase 2Not yet recruitingUniversity Hospital, Strasbourg, France1202027-08-012026-08-20

Showing 20 of 29601. Sign in to see all of them.

Narrower conditions

Multiple Myeloma (3675)  ·  Leukemia, Myeloid, Acute (3594)  ·  Lymphoma (3020)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2524)  ·  Leukemia (2382)  ·  Lymphoma, Non-Hodgkin (2288)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2019)  ·  Myelodysplastic Syndromes (1970)  ·  Lymphoma, Follicular (1876)  ·  Lymphoma, Large B-Cell, Diffuse (1833)  ·  Anemia (1670)  ·  Hematologic Neoplasms (1449)  ·  Recurrence (1438)  ·  Hodgkin Disease (1302)  ·  Lymphoma, Mantle-Cell (1212)

Broader conditions

Hematologic Diseases (21722)  ·  Neoplasms (18789)  ·  Neoplasms by Histologic Type (18051)  ·  Immune System Diseases (15912)  ·  Lymphoproliferative Disorders (14178)  ·  Immunoproliferative Disorders (14054)  ·  Lymphatic Diseases (12750)  ·  Pathological Conditions, Signs and Symptoms (7906)  ·  Pathologic Processes (7192)  ·  Leukemia (6421)  ·  Hemorrhagic Disorders (6356)  ·  Cardiovascular Diseases (5441)  ·  Lymphoma (5295)  ·  Vascular Diseases (5240)

Interventions

Cyclophosphamide (1926)  ·  Rituximab (1539)  ·  Dexamethasone (1351)  ·  Cytarabine (1141)  ·  Lenalidomide (900)  ·  fludarabine (862)  ·  Vincristine (729)  ·  Bortezomib (698)  ·  Etoposide (689)  ·  Doxorubicin (661)  ·  Prednisone (657)  ·  fludarabine phosphate (628)  ·  venetoclax (628)  ·  Azacitidine (611)  ·  Methotrexate (588)

Sponsors

M.D. Anderson Cancer Center (840)  ·  National Cancer Institute (NCI) (827)  ·  Novartis Pharmaceuticals (416)  ·  Memorial Sloan Kettering Cancer Center (353)  ·  Hoffmann-La Roche (287)  ·  Institute of Hematology & Blood Diseases Hospital, China (283)  ·  Assistance Publique - Hôpitaux de Paris (279)  ·  Fred Hutchinson Cancer Center (271)  ·  Celgene (236)  ·  Mayo Clinic (233)  ·  National Heart, Lung, and Blood Institute (NHLBI) (225)  ·  City of Hope Medical Center (220)  ·  Pfizer (213)  ·  GlaxoSmithKline (204)  ·  St. Jude Children's Research Hospital (202)

Countries

United States (13843)  ·  China (3767)  ·  France (3154)  ·  Italy (2421)  ·  Germany (2210)  ·  United Kingdom (2062)  ·  Spain (1971)  ·  Canada (1939)  ·  Australia (1334)  ·  South Korea (1069)  ·  Belgium (1064)  ·  Netherlands (1019)  ·  Poland (974)  ·  Japan (861)  ·  Israel (797)

Results publications

PMID 34515338, PMID 36005278, PMID 41671463, PMID 36791280, PMID 32499241, PMID 41114449, PMID 35622074, PMID 34932836, PMID 40135712, PMID 32632956, PMID 26965694, PMID 37975597, PMID 33783815, PMID 34398557, PMID 36240296, PMID 38780066, PMID 31401903, PMID 33394722, PMID 40550489, PMID 19005182, PMID 24383844, PMID 25527568, PMID 33242441, PMID 33357481, PMID 38502198, PMID 39319495, PMID 39563886, PMID 40750723, PMID 23524640, PMID 26373676, PMID 29674506, PMID 30957581, PMID 31221778, PMID 31375516, PMID 34724566, PMID 34922648, PMID 35235189, PMID 35244208, PMID 35829925, PMID 36064577, PMID 36184192, PMID 37022569, PMID 37192741, PMID 37254256, PMID 37505794, PMID 38620092, PMID 22689675, PMID 23065508, PMID 23620574, PMID 27209293

NIH funding

2023 (282), 2017 (151), 2016 (149), 2018 (144), 2015 (143), P30CA033572 (143), 2014 (140), 2019 (123), P30CA015704 (121), 2009 (101), 2025 (99), P30CA015083 (93), U10CA032102 (88), 2008 (74), P30CA016672 (73)